SynCore drug trial shows ‘no statistical significance’SILVER LINING: Even though no application for the cancer drug’s approval can be filed, the firm would continue its development based on the results, it saidBy Kao Shih-ching / Staff reporterThe unblinding of phase 3 trial data of SynCore Biotechnology Co Ltd’s (杏國新藥) newly developed pancreatic cancer drug SB05PC showed no statistical significance when compared with the control group, the drugmaker said yesterday. The trials tested whether people taking the drug would on average live significantly longer than those in the control group, it added. The disease control rate averaged 59.38 percent in the treatment group, compared with 48.86 percent in the control group; the objective response rate was 11.46 percent in the treatment group, compared with 6.82 percent in the control group; and response to the drug averaged 4.1 months in the treatment group, compared with 5.6 months in the control group, it said. SB05PC was developed as a second-line treatment to be combined with chemotherapy drug gemcitabine for patients who do not respond well to first-line drug Folfirinox, SynCore said. Trail participants either received SB05PC in combination with gemcitabine, or only gemcitabine in the control group, it said.

Source: Taipei Times October 22, 2021 04:10 UTC